FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005756701> ?p ?o ?g. }

• W2005756701 endingPage "138" @default.
• W2005756701 startingPage "132" @default.
• W2005756701 abstract "BACKGROUND The relative amounts of Bcl-2 and Bax proteins determine cell survival or death following an apoptotic stimulus. To clarify the molecular mechanism of cell death after radiotherapy or thermoradiotherapy and its relation to the response of AJCC/UICC Stage IIIB cervical carcinomas, the expression of Bax and Bcl-2 proteins was investigated both before and in the course of treatment given during this study. METHODS Thirty-seven patients with Stage IIIB carcinoma of the uterine cervix were treated with external beam irradiation to the pelvis combined with iridium-192 high-dose-rate intracavitary brachytherapy. All patients were randomized to one of the following two groups: the radiotherapy (RT) group of 19 patients who were given radiotherapy alone, and the thermoradiotherapy (TRT) group of 18 patients who were given 3 sessions of hyperthermia in addition to RT. Specimens of the cervical tumors were obtained by punch biopsy both before and in the course of the treatment (after a total dose of 10.8 grays [Gy] for the RT group or after 10.8 Gy plus 1 session of hyperthermia for the TRT group). The tumor sections were stained with anti-Bax and anti-Bcl-2 monoclonal antibody. On the basis of the percentage of immunopositive cells, both pretreatment and posttreatment samples were scored. Furthermore, relative changes in protein expression were determined by comparing the pretreatment scores with those in the course of treatment. In addition, treatment response was evaluated. RESULTS A complete response was achieved in 52.6% (10 of 19) of the RT group versus 83.3% (15 of 18) of the TRT group (P = 0.049). Better tumor control was accompanied by increased Bax expression, i.e., 10.5% (2 of 19) of the RT group versus 44.4% (8 of 18) of the TRT group (P = 0.02). The respective number of patients who partially responded (PR) or did not respond to treatment (NC) was 26.3% (5 of 19) and 21.1% (4 of 19) of the RT group versus 11.1% (2 of 18) and 5.6% (1 of 18) of the TRT group (P = 0.2 for both the PR and NC subgroups). CONCLUSIONS TRT was found to result in better treatment responses than RT for patients with Stage IIIB cervical carcinoma. An additive or synergistic antitumor effect of TRT is likely to occur through induction of apoptosis involving one of the bax pathways. Cancer 2000;88:132–8. © 2000 American Cancer Society." @default.
• W2005756701 created "2016-06-24" @default.
• W2005756701 creator A5001587891 @default.
• W2005756701 creator A5016963845 @default.
• W2005756701 creator A5038315393 @default.
• W2005756701 creator A5046779019 @default.
• W2005756701 creator A5056534774 @default.
• W2005756701 creator A5056542748 @default.
• W2005756701 creator A5061746144 @default.
• W2005756701 creator A5086521398 @default.
• W2005756701 date "2000-01-01" @default.
• W2005756701 modified "2023-10-01" @default.
• W2005756701 title "Bax and Bcl-2 protein expression following radiation therapy versus radiation plus thermoradiotherapy in stage IIIB cervical carcinoma" @default.
• W2005756701 cites W1835948467 @default.
• W2005756701 cites W1965202064 @default.
• W2005756701 cites W1980942225 @default.
• W2005756701 cites W1982328984 @default.
• W2005756701 cites W1985688442 @default.
• W2005756701 cites W1988335634 @default.
• W2005756701 cites W1988734683 @default.
• W2005756701 cites W2006812742 @default.
• W2005756701 cites W2033864593 @default.
• W2005756701 cites W2037528907 @default.
• W2005756701 cites W2052268236 @default.
• W2005756701 cites W2055430838 @default.
• W2005756701 cites W2058591356 @default.
• W2005756701 cites W2078581194 @default.
• W2005756701 cites W2081894694 @default.
• W2005756701 cites W2084303063 @default.
• W2005756701 cites W2097768542 @default.
• W2005756701 cites W2109327605 @default.
• W2005756701 cites W2112218568 @default.
• W2005756701 cites W2134979684 @default.
• W2005756701 cites W2141190082 @default.
• W2005756701 cites W2148035015 @default.
• W2005756701 cites W2170801441 @default.
• W2005756701 cites W2223163871 @default.
• W2005756701 cites W2274400998 @default.
• W2005756701 doi "https://doi.org/10.1002/(sici)1097-0142(20000101)88:1<132::aid-cncr18>3.0.co;2-h" @default.
• W2005756701 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10618615" @default.
• W2005756701 hasPublicationYear "2000" @default.
• W2005756701 type Work @default.
• W2005756701 sameAs 2005756701 @default.
• W2005756701 citedByCount "51" @default.
• W2005756701 countsByYear W20057567012013 @default.
• W2005756701 countsByYear W20057567012015 @default.
• W2005756701 countsByYear W20057567012016 @default.
• W2005756701 countsByYear W20057567012018 @default.
• W2005756701 countsByYear W20057567012019 @default.
• W2005756701 countsByYear W20057567012020 @default.
• W2005756701 crossrefType "journal-article" @default.
• W2005756701 hasAuthorship W2005756701A5001587891 @default.
• W2005756701 hasAuthorship W2005756701A5016963845 @default.
• W2005756701 hasAuthorship W2005756701A5038315393 @default.
• W2005756701 hasAuthorship W2005756701A5046779019 @default.
• W2005756701 hasAuthorship W2005756701A5056534774 @default.
• W2005756701 hasAuthorship W2005756701A5056542748 @default.
• W2005756701 hasAuthorship W2005756701A5061746144 @default.
• W2005756701 hasAuthorship W2005756701A5086521398 @default.
• W2005756701 hasConcept C126322002 @default.
• W2005756701 hasConcept C142724271 @default.
• W2005756701 hasConcept C146357865 @default.
• W2005756701 hasConcept C151730666 @default.
• W2005756701 hasConcept C2775934546 @default.
• W2005756701 hasConcept C2777416452 @default.
• W2005756701 hasConcept C2777546739 @default.
• W2005756701 hasConcept C2779949491 @default.
• W2005756701 hasConcept C2989005 @default.
• W2005756701 hasConcept C509974204 @default.
• W2005756701 hasConcept C71924100 @default.
• W2005756701 hasConcept C86803240 @default.
• W2005756701 hasConceptScore W2005756701C126322002 @default.
• W2005756701 hasConceptScore W2005756701C142724271 @default.
• W2005756701 hasConceptScore W2005756701C146357865 @default.
• W2005756701 hasConceptScore W2005756701C151730666 @default.
• W2005756701 hasConceptScore W2005756701C2775934546 @default.
• W2005756701 hasConceptScore W2005756701C2777416452 @default.
• W2005756701 hasConceptScore W2005756701C2777546739 @default.
• W2005756701 hasConceptScore W2005756701C2779949491 @default.
• W2005756701 hasConceptScore W2005756701C2989005 @default.
• W2005756701 hasConceptScore W2005756701C509974204 @default.
• W2005756701 hasConceptScore W2005756701C71924100 @default.
• W2005756701 hasConceptScore W2005756701C86803240 @default.
• W2005756701 hasIssue "1" @default.
• W2005756701 hasLocation W20057567011 @default.
• W2005756701 hasLocation W20057567012 @default.
• W2005756701 hasOpenAccess W2005756701 @default.
• W2005756701 hasPrimaryLocation W20057567011 @default.
• W2005756701 hasRelatedWork W2155941014 @default.
• W2005756701 hasRelatedWork W2327355418 @default.
• W2005756701 hasRelatedWork W2356105190 @default.
• W2005756701 hasRelatedWork W2384708512 @default.
• W2005756701 hasRelatedWork W2413110750 @default.
• W2005756701 hasRelatedWork W2432975745 @default.
• W2005756701 hasRelatedWork W4206581437 @default.
• W2005756701 hasRelatedWork W4220908969 @default.
• W2005756701 hasRelatedWork W4243514755 @default.
• W2005756701 hasRelatedWork W4387160257 @default.

• next